

# 1<sup>ST</sup> INTERNATIONAL CONSENSUS CONFERENCE

Management of the  
Kidney Transplant  
Patient with Cancer  
Rome, 30 – 31 January 2020



Scientific Coordinator: Jacopo Romagnoli

AULA BRASCA – UNIVERSITÀ CATTOLICA DEL SACRO CUORE  
FONDAZIONE POLICLINICO UNIVERSITARIO A. GEMELLI IRCCS

## PROGRAMME



# Endorsement



# Committees

## Organising Committee

Jacopo Romagnoli  
Giovanni Scambia  
Giampaolo Tortora  
Vincenzo Valentini

## Scientific Committee

Jacopo Romagnoli  
*Scientific Coordinator*  
Anna Acampora  
*Methodological Coordinator*  
Stefania Boccia  
Giuseppe Grandaliano  
Stefan Hohaus  
Roberto Iacovelli  
Roberto Iezzi  
Umberto Maggiore  
Ketty Peris  
Ernesto Rossi  
Giuseppe Scaletta  
Giovanni Schinzari  
Luca Tagliaferri

## Work Group Members

Anna Acampora  
Valentina Bianchi  
Andrea D'Aviero  
Ilaria Esposito  
Stefan Hohaus  
Valentina Lancellotta  
Elena Maiolo  
Filippo Paoletti  
Alessandro Posa  
Ernesto Rossi  
Giuseppe Scaletta  
Giovanni Schinzari  
Gionata Spagnoletti  
Luca Tagliaferri

## Discussants and Chairs

Luigi Biancone  
Emilio Bria  
Vincenzo Cantaluppi  
Franco Citterio  
Valeriana Colombo  
Laura Cosmai  
Valerio Di Paola  
Alessandro Di Stefani  
Paola Donato  
Lucrezia Furian  
Maria Antonietta Gambacorta  
Giuseppe Grandaliano  
Rosario Francesco Grasso  
Barbara Jereczek  
György Kovács  
Mario Luppi  
Umberto Maggiore  
Nizam Mamode  
Alessandra Palmisano  
Ketty Peris  
Camillo Porta  
Søren Schwartz Sorensen  
Giampaolo Tortora  
Vincenzo Valentini  
Andrea Veltri  
Fabio Vistoli  
Bruno Watschinger

## Thursday, 30 January 2020

- 14:15 – 14:45      **WELCOME**  
Institutional Greetings
- 14:45 – 15:00      **PRESENTATION OF THE CONFERENCE METHODOLOGY**  
Jacopo Romagnoli (*Rome*)
- 15:00 – 18:00      **SESSION I**  
**INTEGRATED THERAPY**  
Moderators: Vincenzo Valentini (*Rome*), Valerio Di Paola (*Rome*)
- 15:00 – 15:40      **Does withdrawing antimetabolites and/or CNI inhibitors and/or mTOR-inhibitors as opposed to continuing maintenance immunosuppression improve patient survival in kidney transplant recipients with cancer undergoing radiotherapy?**
- Presenter: Luca Tagliaferri (*Rome*)
- 1<sup>st</sup> discussant: Valeriana Colombo (*Milan*)
  - 2<sup>nd</sup> discussant: Barbara Jerezczek (*Milan*)
  - Discussion and voting
- 15:40 – 16:20      **Should a kidney transplant patient with cancer avoid standard radiotherapy technique (EBRT, BT, SBRT, protons), dose and volume in order to preserve the transplanted kidney?**
- Presenter: Valentina Lancellotta (*Rome*)
- 1<sup>st</sup> discussant: Vincenzo Cantaluppi (*Novara*)
  - 2<sup>nd</sup> discussant: Maria Antonietta Gambacorta (*Rome*)
  - Discussion and voting
- 16:20 – 16:40      Coffee break

## Thursday, 30 January 2020

16:40 – 17:20

In case of cancer of the transplanted kidney, is focal treatment (thermoablation, radiofrequency, brachytherapy, electrochemotherapy, cryoablation, stereobody radiotherapy, protons) indicated as the standard treatment as opposed to graft nephrectomy?

Presenter: Alessandro Posa (*Rome*)

- 1<sup>st</sup> discussant: Lucrezia Furian (*Padua*)
- 2<sup>nd</sup> discussant: Rosario Francesco Grasso (*Rome*)
- Discussion and voting

17:20 – 18:00

In case of focal treatment, is percutaneous approach (thermoablation, radiofrequency, brachytherapy, electrochemotherapy, cryoablation) indicated as the standard treatment as opposed to external beam radiotherapy (stereobody radiotherapy, protons)?

Presenter: Roberto Iezzi (*Rome*)

- 1<sup>st</sup> discussant: György Kovács (*Lübeck, Germany*)
- 2<sup>nd</sup> discussant: Andrea Veltri (*Turin*)
- Discussion and voting

18:00 – 18:10

### **CONCLUSIONS**

Jacopo Romagnoli (*Rome*)

## Friday, 31 January 2020

- 08:45 – 09:00      **PRESENTATION OF THE CONFERENCE METHODOLOGY**  
Jacopo Romagnoli (*Rome*)
- 09:00 – 11:00      **SESSION IIA**  
**IMMUNOSUPPRESSIVE THERAPY**  
Moderators: Franco Citterio (*Rome*), Umberto Maggiore (*Parma*)
- 09:00 – 09:40      **Should immunosuppression be stopped or modified before oncological surgery in the kidney transplant recipient?**
- Presenter: Giuseppe Scaletta (*Rome*)
- 1<sup>st</sup> discussant: Nizam Mamode (*London, UK*)
  - 2<sup>nd</sup> discussant: Fabio Vistoli (*Pisa*)
  - Discussion and voting
- 09:40 – 10:20      **Does maintaining as opposed to withdrawing or reducing calcineurin inhibitors in kidney transplant recipients with non-metastatic, non-skin cancer undergoing chemotherapy worsen patient or graft survival?**
- Presenter: Valentina Bianchi (*Rome*)
- 1<sup>st</sup> discussant: Bruno Watschinger (*Vienna, Austria*)
  - 2<sup>nd</sup> discussant: Laura Cosmai (*Milan*)
  - Discussion and voting
- 10:20 – 11:00      **Does the switch from calcineurin inhibitors to mTOR-inhibitors improve patient or graft survival of kidney transplant recipients with metastatic non-skin cancer undergoing chemotherapy?**
- Presenter: Gionata Spagnoletti (*Rome*)
- 1<sup>st</sup> discussant: Søren Schwartz Sørensen (*Copenhagen, Denmark*)
  - 2<sup>o</sup> discussant: Laura Cosmai (*Milan*)
  - Discussion and voting
- 11:00 – 11:20      Coffee Break

## Friday, 31 January 2020

- 11:20 – 12:40 **SESSION IIB**  
**IMMUNOSUPPRESSIVE THERAPY AND IMMUNOTHERAPY**  
Moderators: Giuseppe Grandaliano (*Rome*), Ketty Peris (*Rome*)
- 11:20 – 12:00 Does maintaining as opposed to withdrawing calcineurin inhibitors in kidney transplant recipients with PTLD, undergoing first-line chemotherapy worsen patient or graft survival?  
  
Presenter: Stefan Hohaus (*Rome*)
  - 1<sup>st</sup> discussant: Paola Donato (*Verona*)
  - 2<sup>nd</sup> discussant: Mario Luppi (*Modena*)
  - Discussion and voting
- 12:00 – 12:40 Does the use of checkpoint inhibitors in kidney transplant recipients with metastatic skin and non-skin cancer have a negative impact on patient or graft survival?  
  
Presenters: Ernesto Rossi / Ilaria Esposito (*Rome*)
  - 1<sup>st</sup> discussant: Alessandra Palmisano (*Parma*)
  - 2<sup>nd</sup> discussant: Alessandro Di Stefani (*Rome*)
  - 3<sup>rd</sup> discussant: Emilio Bria (*Rome*)
  - Discussion and voting
- 12:40 – 13:00 **Lectio Magistralis**  
**HOW TO DEAL WITH A SURGICAL CRISIS**  
Nizam Mamode (*London, UK*)
- 13:00 – 14:00 Lunch

## Friday, 31 January 2020

14:00 – 17:00

**Session III**  
**CHEMOTHERAPY**

Moderators: Giampaolo Tortora (*Rome*), Mario Luppi (*Modena*)

14:00 – 14:40

**Can hormone therapy be safely used in kidney transplant recipients with cancer?**

Presenter: Giovanni Schinzari (*Rome*)

- 1<sup>st</sup> discussant: Giuseppe Grandaliano (*Rome*)
- 2<sup>nd</sup> discussant: Emilio Bria (*Rome*)
- Discussion and voting

14:40 – 15:20

**Can anti-angiogenic drugs be safely used in kidney transplant recipients with cancer?**

Presenter: Ernesto Rossi (*Rome*)

- 1<sup>st</sup> discussant: Giuseppe Grandaliano (*Rome*)
- 2<sup>nd</sup> discussant: Camillo Porta (*Pavia*)
- Discussion and voting

15:20 – 16:00

**Can platinum salts be safely used in kidney transplant recipients with cancer?**

Presenter: Giovanni Schinzari (*Rome*)

- 1<sup>st</sup> discussant: Luigi Biancone (*Turin*)
- 2<sup>nd</sup> discussant: Camillo Porta (*Pavia*)
- Discussion and voting

16:00 – 16:20

Coffee Break

16:20 – 17:00

**SUMMARY AND CONCLUSIONS**

Jacopo Romagnoli (*Rome*)

# INFORMATION

## ECM (only for Italian participants)

L'evento è stato accreditato presso la Commissione Nazionale per la Formazione Continua in Medicina (ID evento 282370) e ha ottenuto n. 3 crediti formativi per la figura professionale di

- Medico Chirurgo con la specializzazione nelle seguenti discipline: *Anestesia e Rianimazione; Chirurgia Generale; Dermatologia e Venereologia; Ematologia; Ginecologia E Ostetricia; Nefrologia; Oncologia; Radioterapia; Radiodiagnostica*
- Infermiere
- Infermiere pediatrico

---

*Thanks to the following companies for the unconditional support*



Organising Secretariat

**ega** worldwide  
congresses & events

Viale Tiziano, 19 – 00196 Rome  
Tel. +39 06328121 Fax +39 0239293109  
consensus.kidney@ega.it